Advair

Showing 15 posts of 16 posts found.

mylan_building

Mylan’s Wixela becomes first FDA-approved generic version of GSK’s Advair inhaler

January 31, 2019
Sales and Marketing Advair, COPD, FDA, Wixela, asthma, generic, pharma

Mylan’s Wixela has become the first generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler to …

mylan_building

FDA knocks back Mylan’s Advair generic for second time

June 14, 2018
Sales and Marketing Advair, FDA, GSK, Mylan, pharma

The FDA has rejected Mylan’s generic version of GlaxoSmithKline’s Advair for the second time following its knockback last year, citing …

Hikma’s Advair generic delayed in the US

March 12, 2018
Sales and Marketing Advair, FDA, GSK, GlaxoSmithKline, pharma

Hikma Pharmaceuticals has been knocked back with the news that the FDA has delayed approval of its generic lung treatment …

teva_canada

Teva launches competitors to GSK’s Advair inhaler

April 21, 2017
Medical Communications, Sales and Marketing Advair, AirDuo, GSK, Teva, asthma

GSK has been anticipating competition to its Advair for two years and Teva has announced that it will be the …

Mylan’s generic of best-selling GSK drug delayed by FDA

March 30, 2017
Sales and Marketing Advair, GSK, Mylan

Mylan’s plan to bring its generic competitor to GSK’s best-selling respiratory drug, Advair, has hit a major snag after it …

Breo image

GSK and Theravance see FDA nod for asthma indication

March 20, 2015
Sales and Marketing Advair, AstraZeneca, Dulera, FDA, Foradil, GSK, Merck, Symbicort, Theravance, asthma, breo, budesonide/formoterol fumarate dihydratem, ellipta, fluticasone propionate, formoterol fumarate, mometasone/formoterol

An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …

GSK image

GSK blames respiratory woes as sales drop

February 5, 2015
Sales and Marketing Advair, GSK, GlaxoSmithKline, HIV, ViiV, Witty, anoro ellipta, breo, lovaza, q4, sales

GlaxoSmithKline’s respiratory business has been flagged as the key factor in the firm’s fourth quarter financial misfortunes, as its total …

Novartis image

Novartis seeks FDA approval for lung drugs

January 8, 2015
Sales and Marketing Advair, FDA, GSK, NVA237, Novartis, QVA149, Seretide, asthma, lung copd

Novartis has submitted two new lung treatments for FDA approval after ‘robust’ Phase III trial results. If approved, QVA149 and …

GSK image

GSK confirms hundreds of US job cuts

December 3, 2014
Medical Communications, Research and Development, Sales and Marketing Advair, GSK, Parexel, RTP, anoro, breo, job cuts, respiratory

GlaxoSmithKline has finally confirmed the rumours that it is cutting hundreds of US jobs as the UK firm struggles to …

Viiv image

GSK mulls $27 billion ViiV sell-off

October 23, 2014
Medical Communications, Sales and Marketing AIDS, Advair, GSK, HIV, Pfizer, Q3, Shionogi, Tivicay, ViiV

After a difficult few years and another poor quarter, GlaxoSmithKline has announced that it is looking to float its fast-growing …

boehringer_angle_22

Boehringer’s Striverdi gains FDA approval

August 1, 2014
Sales and Marketing Advair, COPD, Pfizer, Spiriva, asthma, olodaterol

Boehringer Ingelheim’s new lung drug Striverdi has gained US approval for patients with chronic obstructive pulmonary disorder. Striverdi Respimat (olodaterol), …

GSK image

GSK sees profit fall

May 1, 2014
Sales and Marketing Advair, China, GSK, Novartis, Q1, Seretide, Witty

GlaxoSmithKline has seen revenue and profit plummet in the first quarter of 2014. The UK-based company saw turnover fall 13% …

Eklira image

Almirall’s COPD drug launched in Europe

September 20, 2012
Sales and Marketing Advair, Almirall, Eklira, Genuair, Seretide, Spiriva

Almirall has launched COPD treatment Eklira in Denmark following approval from the European Commission. Phase III trials demonstrated that Eklira …

GSK severe asthma drug progresses to Phase III

August 20, 2012
Research and Development, Sales and Marketing Advair, GSK, Phase II, asthma, phase III

GlaxoSmithKline’s severe asthma drug mepolizumab has impressed in a mid-stage study, meaning it can now progress into Phase III testing. …

Underwhelming results for GSK’s Relovair

January 10, 2012
Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma

GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …

Latest content